The round was led by $8m from Leaps by Bayer and increased the microbiome skin treatment developer's total funding to $34m.
Pharmaceutical and agricultural product maker Bayer has invested $8m through its Leaps by Bayer unit to lead a $17m series B round for US-based dermatology treatment developer Azitra.
Venture capital firm Bios Partners and Connecticut Innovations, the VC arm of the US state of Connecticut, also took part in the round, which lifted the company’s funding to $34m altogether.
Azitra is using proteomics and genetic engineering to develop treatments for dermatological conditions like acne, atopic dermatitis or rosacea, based on…
